Dade Behring to distribute ZymeTx influenza diagnostic:
This article was originally published in Clinica
Executive Summary
Dade Behring is to handle distribution for ZymeTx' ZstatFlu influenza diagnostic to 25,000 US hospital and reference laboratories. ZymeTx claimed a 50% share of the 230,000 point-of-care tests administered in physicians' offices last year, but said the reference labs conducted more than twice as many tests. With the advent of effective anti-flu therapeutics, that market is predicted to grow to 20 million prescriptions by 2004/2005, with a potential one-to-one ratio between diagnostics and therapeutics, according to ZymeTx.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.